No Data
No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): Nivolumab injection obtained a drug clinical trial approval letter.
On August 8th, Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd., received the National Medical Products Administration's approval and issuance of the "Drug Clinical Trial Approval Notice" for Fuanaxijuzhandankang injection. Clinical trials will be conducted in the near future. Fuanaxijuzhandankang injection is a recombinant humanized monoclonal antibody targeting human IL-17A independently developed by the company, intended to be used for the treatment of autoimmune diseases related to the IL-17 pathway.
Medicilon Y Hengrui Pharma Profundizan La Colaboración Estratégica
Medicilon Et Hengrui Pharma Renforcent Leur Collaboration Stratégique Pour Soutenir L'innovation Dans Les ADC, Les Petits Acides Nucléiques Et Les Médicaments CGT
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
CSC: Rich pipeline of IL-17A and other target drugs, related drugs are expected to gradually achieve domestic production.
There is a rich pipeline of targeted drugs for IL-17A, IL-4R, JAK, IL-23, and other targets, some of which have already been approved for domestic pipelines or applied for approval. Relevant drugs are expected to gradually achieve domestic production in the treatment of autoimmune diseases in China.
No Data